CHARLESTOWN, MA
September 14, 2005

PHT Corporation, the leading provider of electronic patient reported outcome (ePRO) solutions used in over 160 trials worldwide, has entered into a strategic alliance with Dendrite Japan Corporation that will allow Dendrite Japan to resell PHT’s ePRO products to new and existing customers. Through this relationship, PHT will become the first ePRO provider to implement eDiaries for use in clinical research in Japan. Dendrite Japan will provide local Help Desk, Project Management and Support Services to biopharmaceutical clients using PHT’s market-leading LogPad® and StudyPadTM Systems. Dendrite will market PHT’s complete ePRO solution including LogPad, StudyPad and StudyWorksTM, PHT’s online solution that enables site coordinators and study sponsors to better manage subject compliance and enrollment with real-time data access.

“We are extremely excited that Dendrite Japan has elected to market PHT’s ePRO solutions to its distinguished customer base,” said Phil Lee, PHT President and CEO. “Japan is the third-largest pharmaceutical market in the world, but study sponsors are now just beginning to adopt electronic patient diaries. Given the rapid increase of ePRO acceptance in diverse geographies around the globe, there is a tremendous opportunity for growth in Japan.”

PHT and Dendrite together are uniquely positioned to meet the specific requirements of the growing Japanese ePRO market. A thorough understanding of these needs has enabled PHT and Dendrite to develop an effective ePRO offering for Japanese sponsors, subjects and sites. The two companies have been collaborating for more than two years to actively lay the groundwork for the first-ever ePRO trial in Japan.

“By partnering with PHT, we are able to provide our Japanese clients with the most complete solution available,” said Jean-Paul Modde, Senior Vice President of Dendrite International, Inc., parent company of Dendrite Japan. “Japan’s robust biotechnology and pharmaceutical industries are looking for new and innovative ways to improve clinical data quality and reduce trial timelines – and ePRO solutions provide both. In addition to reselling PHT’s ePRO products, we will also deliver local support services necessary to ensure our clients receive the same professional quality that they have come to expect from Dendrite Japan.”

About Dendrite Japan Corporation
Dendrite Japan Corporation is based in Osaka and Tokyo and provides product and service solutions to leading Japanese and international pharmaceutical wholesalers and manufacturers, including AstraZeneca, Bristol-Meyers, Kissei, Ono Pharmaceutical, Pfizer, Takeda, Teijin Ltd., Torii, and Tsumura & Co.

About Dendrite International, Inc.
Dendrite develops and delivers solutions that increase the productivity of sales,
marketing, and clinical processes for pharmaceutical and other life sciences clients. For more information, visit www.dendrite.com.

About PHT Corporation
PHT Corporation is the market-leading provider of electronic patient reported outcome (ePRO) solutions used in over 170 trials worldwide. More than 65 biopharmaceutical and medical device companies, including 13 of the top 15 drug development firms in the world, rely on PHT’s innovative and comprehensive ePRO solutions for their Phase I-IV clinical studies. PHT’s integrated Product Suite enables successful clinical trials by improving data quality, reducing data variance, and providing real-time access to the data collected. FDA and other regulatory authorities have approved new drug applications that include endpoint data collected using PHT’s Product Suite. PHT’s experience includes more than 75,000 subjects at 9,000 clinical sites in 61 languages and 59 countries around the globe. PHT is headquartered in Charlestown, MA, and Geneva, Switzerland. To learn why more biopharmaceutical and medical device companies choose to rely on PHT over any other ePRO provider, please visit www.phtcorp.com.

Media Contact:
Kristopher E. Sarajian
PHT Corporation
617-973-1706
ksarajian@phtcorp.com